Privately-held Swiss biotech Novimmune has announced that its lead program, NI-0501, has been declared eligible for the PRIME (PRIority MEdicine) scheme of the European Medicines Agency (EMA) for the treatment of primary hemophagocytic lymphohistiocytosis (HLH).
The company’s compound is currently in Phase II/III of clinical development to treat HLH, a life-threatening disease of severe hyperinflammation which mainly occurs in children.
Launched only in March of this year, the PRIME scheme has been initiated by the EMA to enhance support for the development of medicines that target an unmet medical need, helping patients to benefit as early as possible from therapies that may significantly improve their health condition or quality of life.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze